Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation- predominant irritable bowel syndrome? A randomized controlled trial

Neurogastroenterology and Motility

Volumn 19, Issue 10, 2007, Pages 821-830

  Foxx Orenstein, A E ^a,c   Camilleri, M ^a   Szarka, L A ^a   Mckinzie, S ^a   Burton, D ^a   Thomforde, G ^a   Baxter, K ^a   Zinsmeister, A R ^b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b Mayo Clinic   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Constipation predominant irritable bowel syndrome; Naltrexone; Serotonin; Small intestine; Tegaserod; Transit

Indexed keywords

NALTREXONE; OPIATE ANTAGONIST; PLACEBO; SEROTONIN 4 AGONIST; TEGASEROD;

ABDOMINAL CRAMP; ADULT; ARTICLE; ASCENDING COLON; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TRANSIT; HUMAN; IRRITABLE COLON; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCINTIGRAPHY; SMALL INTESTINE;

ADULT; CONSTIPATION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL MOTILITY; HUMANS; INDOLES; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; RADIONUCLIDE IMAGING; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN AGONISTS;

EID: 34648822961     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2007.00944.x     Document Type: Article

References (54)

1. Thompson WG. Irritable bowel syndrome: pathogenesis and management.[see comment]. Lancet 1993 341 : 1569 72.
2. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol 2005 39 (4 Suppl. 3 S184 93.
3. Dunlop SP, Coleman NS, Blackshaw E et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005 3 : 349 57.
4. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006 130 : 34 43.
5. Mertz H. Irritable bowel syndrome. N Engl J Med 2003 349 : 2136 46.
6. Camilleri M. Mechanisms in IBS: something old, something new, something borrowed. Neurogastroenterol Motil 2005 17 : 311 6.
7. Jin JG, Foxx-Orenstein A, Grider JR. Stimulation of colonic propulsion by 5-HT4 receptor agonists: synergism by delta opioid receptor agonists. Gastroenterology 1997 112 : A754.
8. Grider JR, Makhlouf GM. Role of opioid neurons in the regulation of intestinal peristalsis. Am J Physiol 1987 253 (2 Pt 1 G226 31.
9. Grider JR. Interplay of somatostatin, opioid, and GABA neurons in the regulation of the peristaltic reflex. Am J Physiol 1994 267 (4 Pt 1 G696 701.
10. Messenger JP, Furness JB. Projections of chemically-specified neurons in the guinea-pig colon. Arch Histol Cytol 1990 53 : 467 95.
11. Grider JR, Makhlouf GM. Identification of opioid receptors on gastric muscle cells by selective receptor protection. Am J Physiol 1991 260 (1 Pt 1 G103 7.
12. Stanniforth D, Pennick M. Pharmacology of renzapride: a new gastrokinetic benzamidewithout dopaminergic properties. Eur J Clin Pharmacol 1990 38 : 161 6.
13. Cherubini E, North RA. Mu and kappa opioids inhibit transmitter release by different mechanisms. Proc Natl Acad Sci U S A 1985 82 : 1860 3.
14. Kojima Y, Takahashi T, Fujina M, Owyang C. Inhibition of cholinergic transmission by opiates in ileal myenteric plexus is mediated by kappa receptor. Involvement of regulatory inhibitory G protein and calcium N-channels. J Pharmacol Exp Ther 1994 268 : 965 70.
15. Kromer W. Reflex peristalsis in the guinea pig isolated ileum is endogenously controlled by kappa opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 1990 341 : 450 4.
16. Waterman S, Costa M, Tonini M. Modulation of peristalsis in the guinea-pig isolated small intestine by exogenous and endogenous opioids. Br J Pharmacol 1992 106 : 1004 10.
17. Knapp R, Malatynska E, Collins N et al. Molecular biology and pharmacology of cloned opioid receptors. FASEB J 1995 9 : 516 25.
18. McLeod R, Parra L, Mutter J et al. Nociceptin inhibits cough in the guinea pig by activatino of ORL1 receptors. Br J Pharmacol 2001 132 : 1175 8.
19. Jin JG, Foxx-Orenstein AE, Grider JR. Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J Pharmacol Exp Ther 1999 288 : 93 7.
20. Foxx-Orenstein AE, Jin JG, Grider JR. 5-HT4 receptor agonists and delta-opioid receptor antagonists act synergistically to stimulate colonic propulsion. Am J Physiol 1998 275 (5 Pt 1 G979 83.
21. Kamm MA, Muller-Lissner S, Talley NJ et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. [erratum appears in Am J Gastroenterol. 2005 Mar;100(3):735]. Am J Gastroenterol 2005 100 : 362 72.
22. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000 118 : 463 8.
23. Muller-Lissner SA, Fumagalli I, Bardhan KD et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001 15 : 1655 66.
24. Novick J, Miner P, Krause R et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002 16 : 1877 88.
25. Kellow J, Lee OY, Chang FY et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.[see comment]. Gut 2003 52 : 671 6.
26. Nyhlin H, Bang C, Elsborg L et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.[see comment]. Scand J Gastroenterol 2004 39 : 119 26.
27. Kurz A, Sessler D. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003 63 : 649 71.
28. Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ III. Functional constipation and outlet delay: a population-based study. Gastroenterology 1993 105 : 781 90.
29. Surrenti E, Rath DM, Pemberton JH, Camilleri M. Audit of constipation in a tertiary referral gastroenterology practice. Am J Gastroenterol 1995 90 : 1471 5.
30. Cremonini F, Mullan BP, Camilleri M, Burton DD, Rank MR. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 2002 16 : 1781 90.
31. Burton DD, Camilleri M, Mullan BP, Forstrom LA, Hung JC. Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. J Nucl Med 1997 38 : 1807 10.
32. Talley NJ, Phillips SF, Wiltgen CM, Zinsmeister AR, Melton LJ III. Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc 1990 65 : 1456 79.
33. Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003 349 : 1360 8.
34. Zelnorm. Tegaserod Maleate. East Hanover, NJ : Novartis Pharmaceuticals, 2004.
35. Zelnorm. Tegaserod Maleate. Dorval, QC : Novartis Pharmaceuticals Canada Inc, 2002.
36. ReVia package insert. Rev 3/97, Rec 6/97. DuPont, USA.
37. ReVia package insert. Rev 2/96, Rec 2/97. DuPont, Canada.
38. Gonzalez J, Brogden R. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988 35 : 192 213.
39. Crabtree B. Review of naltrexone, a long-acting opiate antagonist. Clin Pharm 1984 3 : 273 80.
40. Peres-Reyes M. Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab Dispos 1981 9 : 369 75.
41. Grider JR, Foxx-Orenstein A. Neuroendocrine regulation of intestinal peristalsis. In : Greeley G, ed. Endocrinology of the Gastrointestinal System. Totowa, NJ : Humana Press, 1998 : 295 315.
42. Grider JR, Makhlouf GM. Colonic peristaltic reflex: identification of vasoactive intestinal peptide as mediator of descending relaxation. Am J Physiol 1986 251 (1 Pt 1 G40 5.
43. Bouras EP, Delgado-Aros S, Camilleri M et al. SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography. Gut 2002 51 : 781 6.
44. Camilleri M, Zinsmeister AR, Greydanus MP, Brown ML, Proano M. Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci 1991 36 : 609 15.
45. Heaton K, Radvan J, Cripps H, Mountford R, Braddon F, Hughes A. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 1992 33 : 818 24.
46. Coulie B, Szarka LA, Camilleri M et al. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 2000 119 : 41 50.
47. Grider JR. CGRP as a transmitter in the sensory pathway mediating peristaltic reflex. Am J Physiol 1994 266 (6 Pt 1 G1139 45.
48. Gonenne J, Camilleri M, Ferber I et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005 3 : 784 791.
49. Camilleri M, McKinzie S, Fox J et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004 2 : 895 904.
50. Stivland T, Camilleri M, Vassallo M et al. Scintigraphic measurement of regional gut transit in idiopathic constipation. Gastroenterology 1991 101 : 107 15.
51. Vassallo M, Camilleri M, Phillips S, Brown M, Chapman N, Thomforde G. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 1992 102 : 102 8.
52. Debongnie JC, Phillips SF. Capacity of the human colon to absorb fluid. Gastroenterology 1978 74 : 698 703.
53. Talley N, Camilleri M, Burton D et al. Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers. Aliment Pharmacol Ther 2006 24 : 859 67.
54. Talley N, Locke GR, Lahr B et al. Functional dyspepsia, delayed gastric emptying, and impaired quality of life. Gut 2006 55 : 933 9.